Stephen H. Thorne, Ph.D.
Research Interest: Designing, engineering and testing of targeted strains of vaccinia virus to act as oncolytic agents for the treatment of cancer


Designing, engineering and testing of targeted strains of vaccinia virus to act as oncolytic agents for the treatment of cancer, with special emphasis on;

  • Enhancing systemic delivery, especially in the face of anti-viral immunity.
  • Enhancing early viral spread in the tumor microenvironment.
  • Optimizing viral interaction with the host immune response
  • Development of novel transgenes to be expressed from oncolytic virus vectors, especially constructs capable of inducing a targeted and localized bystander killing effect.
  • Effects of exogenously regulating oncolytic vector transgene function.
  • Effects of combining oncolytic viruses with approved and experimental therapies, especially;
  • Immune cell therapies, both as combination cancer therapies and the use of immune cells as carrier vehicles to deliver viruses to tumors.
  • Cancer vaccines.
  • Chemotherapies, including taxols and cisplatin.
  • Tyrosine Kinase Inhibitors.
  • Monoclonal antibodies, especially anti-immune checkpoint inhibitors.
  • Examination of host-pathogen interactions.
  • Use and development of pre-clinical imaging tools (especially optical imaging) to non-invasively examine molecular events in vivo.



Recent Publications: